Immunoglobulins, also known as antibodies, are the firstly characterized molecules involved in specific immune recognition. In recent decades, the success of antibody therapy in the fields of hematology, oncology, autoimmune diseases, and infections is consistent with the ability of these molecules to activate immune responses. Compared with classical IgG, IgE presents great potential as a therapeutic agent. Based on years of experience, now Creative Biolabs can provide our worldwide clients with professional IgE production and purification services based on the value of quality.
Our Service
At Creative Biolabs, we specialize in providing cutting-edge IgE production and purification services that meet the demanding needs of both academic and industrial clients. Our production processes leverage advanced recombinant DNA technology, coupled with our proprietary Expression System Platform, to generate high-quality IgE antibodies in sufficient quantities for various applications, including research, diagnostics, and therapeutic development.
The IgE production pipeline begins with gene synthesis and vector construction, which are followed by transient transfection of mammalian cells or stable cell line generation. After amplification and protein expression, the IgE antibodies are harvested and purified. Due to its unique properties, IgE purification often involves a multi-step process. Our purification services include a combination of affinity chromatography, ion exchange chromatography, and size-exclusion chromatography to isolate IgE with the highest purity and functionality.
Fig.1 Development of a stable platform for the expression of recombinant IgE.1,3
Service Process
Highlights
-
Customized Expression Systems
We employ advanced expression systems, including CHO, HEK293, and other mammalian cells, ensuring flexibility and efficiency tailored to each project's unique requirements. -
Comprehensive Purification Techniques
Our purification strategies utilize multiple methods, such as affinity chromatography, ion-exchange chromatography, and size-exclusion chromatography, specifically designed to handle IgE's complex properties and ensure the highest purity. -
High Yield and Stability
Through the use of single-cell cloning and stable cell line development, we achieve superior yields of IgE, while also offering glyco-optimization services to improve the antibody's stability and efficacy. -
Scalable Production
We offer scalable IgE production solutions, ranging from small-scale research quantities to large-scale batches for preclinical studies, ensuring that projects of all sizes are accommodated.
Background
IgE is a type of antibody isotype that only has been found in mammals. Synthesized by plasma cells, IgE antibodies have a different structure compared with the conventional IgG1 antibodies. The heavy chain of IgG contains 3 constant domains, while the IgE heavy chain has a total of 4 constant domains. As for the light chain, both of them have 1 variable and 1 constant domain. IgEs are the least abundant circulating antibodies in the serum because of the short half-life (1-3 days compared to 3 weeks of IgG) and the small number of IgE-secreting plasma cells. Despite its scarcity, IgE plays a crucial role in immune defense, particularly in allergic responses and defense against parasitic infections. IgE binds to Fcε receptors on mast cells and basophils, triggering these cells to release histamine and other inflammatory mediators during allergic reactions. Additionally, emerging evidence suggests that IgE may have potential therapeutic implications in the treatment of tumors, making it a molecule of growing interest in both academic research and clinical applications. However, the large-scale production and purification of IgE antibodies pose significant technical challenges. IgE's low abundance in serum, complex glycosylation patterns, and binding properties make its production and purification more complex than that of other immunoglobulin types, such as IgG. These challenges necessitate advanced production techniques and innovative purification methods to ensure high-quality IgE antibodies suitable for therapeutic or research purposes.
Fig.2 IgE is a heavily glycosylated molecule, with 7 documented N-glycan sites.2,3
FAQs
Q1: Why is IgE production more challenging than IgG?
A: IgE is more challenging to produce due to its lower natural abundance, larger molecular size, and complex glycosylation patterns. IgE also tends to aggregate and is more sensitive to denaturation during the production and purification process. At Creative Biolabs, we overcome these challenges by using recombinant technology and advanced expression systems to achieve high-quality yields.
Q2: What applications can your purified IgE antibodies be used for?
A: Our IgE antibodies are suitable for a wide range of applications, including basic research, immunoassays, allergy diagnostics, and therapeutic development. They can also be used in studies exploring IgE's role in anti-parasitic immune responses and cancer immunotherapy.
Q3: What cell expression systems do you use for IgE production?
A: We offer a range of expression systems, including CHO, HEK293, and other mammalian cells. The choice of expression system depends on the client's specific needs, such as yield, scalability, and downstream applications.
Q4: How can I get a custom quote for IgE production and purification services?
A: Clients can reach out to Creative Biolabs through our online inquiry form or directly contact our scientific team to discuss their specific project needs. We provide tailored quotes based on the project's scale, complexity, and customization requirements.
Resource
A Brief Introduction to Non-IgG Antibody - Creative Biolabs 
A Brief Introduction to Non-IgG Antibody -
Creative Biolabs
For further investigation and clinical tests of IgE antibody, obtaining high-quality antibodies on a large scale is a prerequisite. Creative Biolabs is an excellent biotech company that provides professional production and purification services of IgE antibody as well as related services based on our extensive experience and advanced platforms. If you are working on antibodies researches (IgG or non-IgG antibodies), please feel free to contact us for more details.
References
- Crescioli, S.; et al. Engineering and stable production of recombinant IgE for cancer immunotherapy and AllergoOncology. The Journal of Allergy and Clinical Immunology. 2018, 141(4): 1519-1523.
- Chauhan, Jitesh, et al. "IgE antibodies against cancer: efficacy and safety." Antibodies 9.4 (2020): 55.
- Distributed under the Open Access license CC BY 4.0, without modification.
KINDLY NOTE
!! For Research Use Only. Our products and services are NOT intended for diagnostic or therapeutic applications.
